Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -207.84% | -712.42% | -14,232.14% | -127.80% | 52.27% |
| Total Depreciation and Amortization | -37.86% | -16.91% | 7.84% | 35.34% | 82.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.77% | 557.67% | 638.69% | 561.63% | 607.12% |
| Change in Net Operating Assets | -2.12% | 30.20% | 77.65% | -3.91% | -240.52% |
| Cash from Operations | -1,354.28% | -1,506.55% | -85.25% | 34.24% | 111.44% |
| Capital Expenditure | -3,331.38% | -2,829.90% | -2,338.27% | 45.92% | 56.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.88% | 20.07% | 143.91% | -411.95% | 146.69% |
| Cash from Investing | -15.46% | -17.81% | 120.12% | -428.72% | 144.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -66.21% | -69.52% | -99.03% | -98.82% | -97.93% |
| Repurchase of Common Stock | 40.27% | 46.18% | 41.74% | 50.15% | 4.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 100.00% | 100.00% |
| Cash from Financing | 2,401.10% | -90.18% | -99.80% | -99.46% | -98.87% |
| Foreign Exchange rate Adjustments | -424.00% | -373.75% | -24.65% | -123.59% | -132.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -296.57% | -185.52% | -327.79% | -195.65% | 1,155.36% |